Hematologic Cancers News
The risk of breast implant-associated anaplastic large cell lymphoma may be higher than previously reported for women who receive textured implants, according to researchers.
After phase 1, the study will expand in a second phase to test the efficacy of these drugs at the determine dosage.
The purpose of this study is to assess the safety, tolerability, and antitumor activity, as well as recommended dose of brentuximab vedotin in combination with a multiagent chemotherapy regimen.
The authors commented on the CASSINI trial, which evaluated thromboprophylaxis with rivaroxaban, and compared the results to those seen in the AVERT trial.
A retrospective study sought to determine the risk factors for thromboembolism in patients with acute leukemia or lymphoma.
A decrease in gait speed by 0.1 m/s was associated with increases in mortality and utilization of emergency and acute care.
Platelet aggregation and platelet activation were both independently associated with bleeding risk.
Results of this study suggest that the clonal and subclonal characteristics of early-stage CLL shape the dynamics of the disease course.
Patients with CLL who had symptomatic bronchial involvement had a significantly higher proportion of anomalies in small airways and peripheral bronchi.
Patients with relapsed multiple myeloma experiencing CVAEs had inferior survival.
Ibrutinib may impair natural killer cell cytotoxic activity, potentially through off-target inhibition of IL-2–inducible kinase (ITK), an in vitro study suggests.
In a review published in the June 1 issue of The Lancet Oncology, recommendations are presented for use of newer imaging techniques for the diagnosis of multiple myeloma.
An MYD88 mutation, protein expression, and PD-1/PD-L1 expression were not associated with survival in primary central nervous system lymphoma.
The increased risk for infection seen in pediatric patients receiving transplants from unrelated donors could be a result of intensified graft-versus-host disease prophylaxis.
Several different models were found to be equally useful for predicting those at risk of progression in multiple myeloma.
Though the primary survival endpoints were not met in this study, younger patients experienced improved outcomes with ibrutinib.
Researchers sought to compare the cost effectiveness of the treatments used for patients with relapsed/refractory DLBCL.
Early failure after treatment, old age, and treatment regimens not including stem cell transplantation were associated with poorer survival.
“Nonrelapse mortality needs to be defined prospectively for all ongoing CAR-T studies,” said the researchers.
Additional research is needed on the best dose schedule for the drug.